We believe the world is ready for new ways to cure human disease and expand access to better health for all. 

Our Story

We started Emerge in 2008 to innovatively apply paradigm-changing scientific and technological advances to the discovery and development of novel, personalized therapies and affordable, high-quality food. 

Our deep roots in the life sciences in India uniquely position Emerge to help Indian scientists successfully commercialize their discoveries while staying true to their purpose. We provide our founder-scientists with business expertise, commercial knowledge, and extensive networks comprised of highly accomplished leaders in business, science, and technology who have made ELS's work their life’s mission. The result is a singular ecosystem of cutting-edge discovery, go-to-market acumen, and management expertise.

Our Philosophy

Working at the intersection of the genomics, artificial intelligence, and protein engineering revolutions, our team of scientists and entrepreneurs invents solutions - diagnostic tests, medicines, and seeds - that help people live better lives. 

We seek out world-class scientific leaders and founders who have made discoveries and created intellectual property that has the potential for transformative health impact and massive economic value.

Our Team


Mahesh Pratapneni

Founder & Managing Partner

Mahesh Pratapneni is a visionary investor, founder, and strategist in the India life sciences and technology sectors. He is known for building outstanding global teams, differentiated strategies, and successful exits. He currently serves as Executive Director of MedGenome and is on the boards of AgriGenome Labs, Saksin Life Sciences, Theragen, and Emerge Biologics. Mahesh earned his undergraduate degree in electronics and communications from IIT Madras, and his MBA from IIM Calcutta.


Sam Santhosh


Sam Santhosh is an entrepreneur with over 25 years of experience in founding and running successful businesses. Sam is an investor and mentor for many companies and is currently a board member at Impelsys Inc, New York, ePay Healthcare, San Francisco, SciGenom Labs, Cochin, Emerge Ventures, Singapore and the Centre for Commercialization of Antibodies (CCAB) Toronto, Canada. Prior to this Sam was the CEO and Managing Director of California Software Limited (Calsoft) from 1992-2012. He founded Calsoft in 1992 and under Sam’s vision Calsoft rapidly grew from a niche player in the Silicon Valley to a global player with over 1200 employees and presence in 8 countries. Sam took Calsoft public and listed the company in the Indian Stock Exchanges. Sam holds a degree in Mechanical Engineering and an MBA from IIM Calcutta. He is based in San Francisco.


Somasekar Seshagiri


Dr. Somasekar Seshagiri is Principal Scientist at Genentech and directs a state-of-the-art DNA sequencing laboratory at Genentech that serves all of Genentech Research. Dr Sekar is a leading expert in the area of Cancer research, genomics and sequencing, having authored and co-authored over forty articles in peer-reviewed journal including Science and Nature. His laboratory has been at the forefront of understanding underlying genetic changes in cancer genomes through systematic identification of somatic mutations in large number of cancers types and subtypes using a number of techniques including next-generation sequencing. His laboratory is also involved in developing diagnostic and prognostic markers to enable personalized cancer therapy.


Rayman Mathoda


Rayman Mathoda is partner at ELS and CEO of Xome, a leading US real estate data and services company. Formerly she was co-CEO and member of Board of Genesis Capital, acquired by Goldman Sachs in 2018, and, President of Hudson & Marshall, sold to Fidelity National Financial in 2017. Rayman started her career at McKinsey & Co., where she was co-leader of the West Coast healthcare practice. Rayman has an A.B. with honors from Princeton University and an MBA with distinction from the Kellogg Graduate School of Management at Northwestern University. She is a member of Young Presidents Organization and of the board of directors of GenomeAsia100K USA Foundation.


Vishva M. Dixit

Special Advisor

Vishva M. Dixit, M.D., Vice President of Physiological Chemistry at Genentech, Inc. has made many contributions to biomedicine, and his early work on apoptosis is prominent in introductory textbooks of biology and medicine. He is a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and a Foreign Member, European Molecular Biology Organization. Additionally, he serves on the Boards of the Gates Foundation, Howard Hughes Medical Institute, and Keystone Symposia.


Saurabh Agrawal


Saurabh Agrawal, an alumnus of IIM Calcutta, is credited with managing successful IPOs of top Indian companies in the telecom and technology sectors. He is known for his deal-making skill in sectors like telecom, media, technology and infrastructure. Currently Saurabh is Chief Financial Officer at the Tata Group of Companies. His previous experience includes Managing Director, Standard Chartered Bank for South Asia Corporate Finance and Managing Director, DSP Merrill lynch.